

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070019 A1(51) International Patent Classification⁷: **A23K 1/00**,
A23L 1/03, A23K 1/18ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number: PCT/EP03/01687

(22) International Filing Date: 18 February 2003 (18.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02075702.7 21 February 2002 (21.02.2002) EP(71) Applicant (for all designated States except US): **SOCI-
ETE DES PRODUITS NESTLE S.A.** [CH/CH]; P.O. Box
353, CH-1800 Vevey (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRETON, Lionel**
[FR/FR]; 14, rue Satory, F-78000 Versailles (FR). **BU-
REAU-FRANZ, Isabelle** [FR/CH]; 27, ch. du Mottier,
CH-1052 Le Mont-Sur-Lausanne (CH).(74) Agent: **THOMAS, Alain**; Avenue Nestlé, 55, CH-1800
Vevey (CH).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PET FOOD COMPOSITION FOR SKIN PHOTOPROTECTION

(57) Abstract: An ingestible composition for the photoprotection of the skin of pets which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast and/or a carotenoid or derivative, included into an ingestible carrier.

WO 03/070019 A1

Pet food composition for skin photoprotection**Field of the invention**

5 The present invention relates to pet food composition, for the photoprotection of the skin, whether before, during and/or after exposure to UV radiation, and to the use of same for preventing and/or attenuating the damage caused by such UV irradiation. It also relates to a method to improve the photoprotection of the skin.

10 Background of the Invention

The continuous decrease of the atmosphere's ozone layer with the concurrent increase of ultraviolet radiation reaching the planet's surface has attracted a great deal of interest in its potential consequence on human health.

15 Indeed, it is known that light radiation of wavelengths of from 320 nm to 400 nm (UV-A) promotes tanning of the human epidermis; such radiation, however, is likely to cause damage to the skin, especially in the case of sensitive skin or skin which is continuously exposed to solar radiation. UV-A rays cause, in particular, a loss in the elasticity of the skin and the appearance of wrinkles, promoting a premature aging thereof. It is also known to this art that light rays having wavelengths of from 280 to 20 320 nm (UV-B) cause erythema and skin burning which can impair the natural development of a tan.

25 Although exposure to ultraviolet radiation is needed to produce vitamin D, growing evidence suggests that extensive exposure to sun-light, in particular to ultraviolet radiation, causes a variety of problems in the skin, including induction of certain skin cancers and induction of accelerated skin ageing.

30 In addition to these established health concerns, research has also provided evidence suggesting that exposure to ultraviolet radiation may negatively affect a variety of

immune responses in living beings both locally, within the UV-irradiated skin, and also systemically, i.e. at sites distant from the irradiated skin.

It is thus necessary, in order to maintain suitable skin quality after exposure to UV radiation, to prepare or treat the skin before the exposure, to protect it during the exposure and even to alleviate the detrimental effects of ultraviolet radiation on the skin, prevent the development of erythema, edema and/or flaking or scaling (hyperkeratosis) of the skin.

There is thus a need in the art for an orally administrable composition which is capable to improve and/or reinforce the photoprotective function of the skin of pets.

Summary of the invention

Accordingly, in a first aspect the present invention aims to provide an ingestable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacteria or a culture supernatant thereof, and ii) at least one yeast, included into an orally acceptable carrier and/or one carotenoid or derivative, included into an ingestable carrier.

The present invention further relates to the use of a photoprotecting effective amount of i) at least one probiotic lactic acid bacteria or a culture supernatant thereof and ii) at least one yeast and/or one carotenoid or derivative, for preparing an ingestable carrier for protecting the skin of pets against radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.

In a last aspect, the invention relates to a method for improving the photoprotective function of the skin of pets, which comprises the step of orally administering to the pet a composition comprising a photoprotecting effective amount of i) at least one

probiotic lactic acid bacteria or a culture supernatant thereof, and ii) at least one yeast, in an ingestible carrier.

5 The invention also provides a method of reducing the effects of ageing in a pet comprising the step of feeding a pet a pet food composition as described above.

The combination according to the present invention has a particular beneficial effect on skin protection and colouration of the skin, that helps to reduce the effects of ultraviolet-related stress on skin .

10

Detailed Description of the Invention

15 Within the following description, "NCC" designates Nestlé Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland). The term "photoprotection" is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.

20 According to the present invention, the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacteria or bifidobacteria or a culture supernatant thereof, and at least one yeast and/or one carotenoid.

25 Indeed, it has now surprisingly and unexpectedly been determined that admixture of these very specific constituents elicits an enhanced effect or response in respect of the photoprotection of the skin.

30 Probiotics are non-pathogenic and non-toxigenic organisms, that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastrointestinal wall and reducing their numbers and reducing or preventing infections. Until now a number of different probiotic micro-organisms have been found, which

all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.

It has now been shown that probiotics do also exert an effect in an individual's body at a location distant from the region in which they colonize it. And particularly, it has been surprisingly found that a composition having a synergistic photoprotective effect on the skin may be obtained by combining into an ingestible carrier, a probiotic micro-organism and a yeast.

In a preferred embodiment, the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular *Lactobacilli*, *Bifidobacteria* or *Enterococci*; and are more preferably *Lactobacillus johnsonii*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus casei* or *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium animalis*, *Bifidobacterium lactis*, *Bifidobacterium infantis*, *Bifidobacterium adolescentis*, *Bifidobacterium pseudocatenulatum*, *Enterococcus faecium*, *Enterococcus sp.* or a mixture thereof.

According to a most preferred embodiment the strains *Lactobacillus johnsonii* NCC 533, *Lactobacillus paracasei* NCC 2461, *Bifidobacterium adolescentis* NCC 251 and *Bifidobacterium longum* NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.

The strain of *Bifidobacterium lactis* (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Denmark) can also be used.

The probiotic microorganism according to the present invention may be included in a live form, semi-active or in desactivated form, e.g. as a lyophilized powder. Also culture supernatants of the microorganisms may be included in the products, optionally in concentrated form. It may also be included in an encapsulated form.

5 When using a supernatant of a probiotic's culture the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s) /metabolite (s). Method and techniques for purifying compounds and detecting the activity thereof in the fractions obtained are well known to the skilled person.

10

The probiotic lactic acid bacteria may be present in the carrier in an amount of at least 10^5 cfu/ g of ingestable carrier, preferably from about 10^5 to 10^{15} cfu/ g of ingestable carrier, and more preferably from 10^7 to 10^{12} cfu/ g of ingestable carrier.

15 It may be incorporated in dispersion form in a suitable vehicle such as water, organic solvents and fatty substances including oils, whether alone or in admixture.

The compositions according to the invention also comprise a yeast. In a preferred embodiment, the yeast is any food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina . In a preferred embodiment, the yeast may be

20 selected from the group consisting of *Debaryomyces*, *Kluyveromyces*, *Saccharomyces*, *Yarrowia*, *Zygosaccharomyces*, *Candida* and *Rhodotorula*, and more preferably *Saccharomyces caerevisiae* (baker's yeast).

25 Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least 10^5 cfu/ g of ingestable carrier, preferably from about 10^5 to 10^{15} cfu/ g of ingestable carrier, and more preferably from 10^7 to 10^{12} cfu/ g of ingestable carrier, said amount depending on the nature and activity of the particular yeast.

30

The carotenoid may be a carotenoid with or without provitamin A activity. It may be β -carotene, γ -carotène, α -carotene, lycopene, zeaxanthine and luteine, or a mixture

thereof. The carotenoid may be from synthetic or natural origin or contained in a natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids are well known in the art. The carotenoid may be present
5 in the carrier in an amount of from $10^{-12}\%$ to 20% by weight and preferably from 0,00001 mg to 50 mg/day and more preferably from 0.001mg to 30mg/day.

A mixture of a plurality of lactic acid bacteria, yeast and/or carotenoids may also be used.
10

The carrier may be any pet food or pharmaceutical product, or a nutritional supplement or a treat, wherein the probiotic microorganism, the yeast and/or carotenoid may be included. Methods for preparing the carrier are common knowledge.
15

The said composition may be administered to the pet as a supplement to its normal diet or as a component of a nutritionally complete pet food. It may also be a pharmaceutical composition.

20 The nutritionally complete pet food composition according to the invention may be in powdered, dried form, a treat or a wet, chilled or shelf stable pet food product. These pet foods may be produced by ways known in the art. Apart from the plant or plant extract, these pet foods may include any one or more of a starch source, a protein source and a lipid source.

25 Suitable starch sources are, for example, grains and legumes such as corn, rice, wheat, barley, oats, soy, and mixtures of these. Suitable protein sources may be selected from any suitable animal or vegetable protein source; for example meat and meal, poultry meal, fish meal, soy protein concentrates, milk proteins, gluten, and the
30 like. For elderly animals, it is preferred for the protein source to contain a high quality protein. Suitable lipid sources include meats, animal fats and vegetable fats.

The choice of the starch, protein and lipid sources will be largely determined by the nutritional needs of the animal, palatability considerations, and the type of product applied. For elderly pets, the pet food preferably contains proportionally less fat than pet foods for younger pets. Furthermore, the starch sources may include one or more of
5 rice, barley, wheat and corn.

The pet food may optionally also contain a prebiotic or another active agent, for example a long chain fatty acid. The amount of prebiotic in the pet food is preferably less than 10% by weight. For example, the prebiotic may comprise about 0.1% to about
10 5% by weight of the pet food. For pet foods which use chicory as the source of the prebiotic, the chicory may be included to comprise about 0.5% to about 10% by weight of the feed mixture; more preferably about 1% to about 5% by weight.

Suitable long chain fatty acids include linoleic acid, alpha-linolenic acid, gamma
15 linolenic acid, eicosapentanoic acid, and docosahexanoic acid. Fish oils are a suitable source of eicosapentanoic acids and docosahexanoic acid. Borage oil, blackcurrant seed oil and evening primrose oil are suitable sources of gamma linoleic acid. Safflower oils, sunflower oils, corn oils and soybean oils are suitable sources of linoleic acid.

20 If necessary, the pet food is supplemented with minerals and vitamins so that they are nutritionally complete. Further, various other ingredients, for example, sugar, salt, spices, seasonings, flavouring agents, and the like may also be incorporated into the pet food as desired.

25 For dried pet food a suitable process is extrusion cooking, although baking and other suitable processes may be used. When extrusion cooked, the dried pet food is usually provided in the form of a kibble. If a prebiotic is used, the prebiotic may be admixed with the other ingredients of the dried pet food prior to processing. A suitable
30 process is described in European patent application No 0850569. If a probiotic microorganism is used, the organism is preferably coated onto or filled into the dried

pet food. A suitable process is described in European patent application No 0862863.

For wet food, the processes described in US patents 4,781,939 and 5,132,137 may be used to produce simulated meat products. Other procedures for producing chunk type products may also be used; for example cooking in a steam oven. Alternatively, loaf type products may be produced by emulsifying a suitable meat material to produce a meat emulsion, adding a suitable gelling agent, and heating the meat emulsion prior to filling into cans or other containers.

In another aspect, the invention relates to a method for improving the photoprotective function of the skin of pets, which comprises the step of orally administering to the pet a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacteria or a culture supernatant thereof, and ii) at least one yeast and/or a carotenoid or its derivative, in an ingestible carrier.

The amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about 10^5 to 10^{12} organisms, which organism may be alive or dead, and 0.00001 to 50 mg of carotenoids would usually be adequate.

The composition is administered to an individual before or during the exposure to ultraviolet radiations, in particular exposure to sun. When the exposure period is foreseeable, it is desirable to start the consumption of the composition from 10 to 20 days before, and to prolong consumption during exposure.

In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative. In said examples to follow, as in the above description, all parts and percentages are given by weight, unless otherwise indicated.

Examples

Example 1 : Dry dog food

5 A feed mixture is made up of about 58% by weight of corn, about 5.5% by weight of corn gluten, about 22% by weight of chicken meal, 2,5% dried chicory, salts, vitamins and minerals making up the remainder.

10 The feed mixture is fed into a preconditioner and moistened. The moistened feed is then fed into an extruder-cooker and gelatinised. The gelatinised matrix leaving the extruder is forced through a die and extruded. The extrudate is cut into pieces suitable for feeding to dogs, dried at about 110°C for about 20 minutes, and cooled to form pellets. At this point, a lyophilized powder of one strain of the following strains : CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 or ATCC 27536 and lyophilized powder of *S.cerevissae* (so that the corresponding amount of each is 15 about 1.0E+05-1.0E+12 cfu / day) can be added and mixed to the product. Furthermore, the same amount of bacteria can be sprayed on the cooled pellets after the pellets are dried at 50-60°C for some minutes.

20 This dry dog food helps to protect the skin's natural defenses of pets against the sun's harmful UV rays.

Example 2: Canned pet food and supplement.

25 A mixture is prepared from 73 % of poultry carcass, pig lungs and beef liver (ground), 16 % of wheat flour, 2 % of dyes, vitamins, and inorganic salts. This mixture is emulsified at 12°C and extruded in the form of a pudding which is then cooked at a temperature of 90°C. It is cooled to 30°C and cut in chunks. 45 % of these chunks are mixed with 55 % of a sauce prepared from 98 % of water, 1 % of dye, and 1 % of guar gum. Tinplate cans are filled and sterilized at 125°C for 40 min. 30 As a probiotic supplement to be mixed with the pet-food before serving, additional packaging (e.g. sachet) with one of the following strains: CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 or ATCC 27536, and β -carotene and lyophilized *S.cerevissae*. The corresponding amount for the pet is about 10^5 - 10^{12} cfu / day microorganism and 0.1 to 50 mg of carotenoids, which can be supplied as a 35 supplement with (e.g. on top of) the can.

Claims

1. An ingestable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast and/or carotenoid or derivative, included into an ingestable carrier.
5
2. A composition according to claim 1, in which the lactic acid bacterium is selected from the group consisting of lactic acid bacteria, preferably Lactobacilli, Bifidobacteria or Enterococci.
10
3. A composition according to claim 1 or 2, in which the lactic acid bacterium is *Lactobacillus johnsonii*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus casei* or *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium animalis*, *Bifidobacterium lactis*, *Bifidobacterium infantis*, *Bifidobacterium adolescentis*, *Bifidobacterium pseudocatenulatum*, *Enterococcus faecium*, *Enterococcus sp.* or a mixture thereof.
15
4. A composition according to one of claims 1 to 3, in which the lactic acid bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168 or CNCM I-2170.
20
5. A composition according to one of claims 1 to 4, in which the probiotic lactic acid bacterium is included into the carrier in a live form, semi-active or in desactivated form, preferably as a lyophilized powder attention.
25
6. A composition according to one of claims 1 to 5, wherein the carotenoid is a carotenoid with or without provitamin A activity, such as β -carotene, γ -carotène, α -carotene, lycopene, zeaxanthine and luteine, or a mixture thereof.
30

7. A composition according to one of claims 1 to 6, wherein the yeast is selected from the group consisting of *Debaryomyces*, *Kluyveromyces*, *Saccharomyces*, *Yarrowia*, *Zygosaccharomyces*, *Candida* and *Rhodotorula*, or a mixture thereof.
- 5 8. A composition according to claim 7, wherein the yeast is *S. cerevisiae*
9. A composition according to one of claims 1 to 8, which is in the form of
- i) a nutritionally complete pet food in a powdered, dried or a wet, chilled or shelf stable form or,
- 10 ii) in the form of a dietary adjunct or a supplement or a treat.
10. Use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one yeast and or carotenoid, for preparing an ingestible carrier for the protection of the skin against solar radiations and attenuating or preventing all related skin disorders.
- 15
11. The use according to claim 10, in which the lactic acid bacterium is *Lactobacillus johnsonii*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus casei* or *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium animalis*, *Bifidobacterium lactis*, *Bifidobacterium infantis*, *Bifidobacterium adolescentis*, *Bifidobacterium pseudocatenulatum*, or a mixture thereof *Bifidobacterium pseudocatenulatum*, *Enterococcus faecium*, *Enterococcus sp.* or a mixture thereof.
- 20
12. The use according to claim 10 or 11, wherein the lactic acid bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 or ATCC 27536.
- 25
13. The use according to one of claims 10 to 12, wherein the yeast is selected from the group consisting of *Debaryomyces*, *Kluyveromyces*, *Saccharomyces*, *Yarrowia*, *Zygosaccharomyces*, *Candida* and *Rhodotorula*, or a mixture thereof.
- 30

14. The use according to one of claims 10 to 13, wherein the probiotic lactic acid bacterium is present in the carrier in an amount of from about 10^5 to 10^{12} cfu/ g carrier, the yeast from about 10^5 to 10^{15} cfu/ g of the carrier.
- 5 15. The use according to one of claims 10 to 13, wherein the carotenoid is present in the carrier in an amount of from $10^{-12}\%$ to 20% by weight.
16. The use according to any of claims 10 to 15, for the preparation of a composition intended for reducing the effects of photoageing in pets.
- 10 17. A method for improving the photoprotective function of the skin of pets, which comprises the step of orally administering to the pet a composition comprising the combination of i) at least one probiotic lactic acid bacteria or a culture supernatant thereof, and ii) at least one yeast and/or carotenoid or derivative, in
- 15 an ingestible carrier.
18. A method according to claim 17, in which the composition is according to claims 1 to 9.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP/01687

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23K1/00 A23L1/03 A23K1/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23K A23L A23C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, FSTA, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 968 569 A (CAVADINI CHRISTOF ET AL) 19 October 1999 (1999-10-19) column 3, line 3 - line 33; claims 1,5,7,10,12,13; example 7 ---	1-5,7-9
X	DATABASE WPI Section Ch, Week 200232 Derwent Publications Ltd., London, GB; Class B04, AN 2002-278805 XP002207609 & RU 2 178 975 C (BORTS M S), 10 February 2002 (2002-02-10) abstract ---	1,2,5,9
X	DE 35 36 342 A (WOLF WALTER DR) 8 October 1987 (1987-10-08) claims 1,10 --- -/-	1,2,10, 11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

5 June 2003

Date of mailing of the international search report

12/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Grittern, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01687

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 2002/039606 A1 (MOTOZONO YUKIHIRO ET AL) 4 April 2002 (2002-04-04) claim 1; examples ----	1-3,5, 7-9
A	WO 01 17365 A (NESTLE SA) 15 March 2001 (2001-03-15) page 4, line 33 -page 5, line 22; example 1 ----	1-3,9,10
A	US 5 702 719 A (DONZIS BYRON A) 30 December 1997 (1997-12-30) claims; example 5 ----	1,9,10
A	FR 2 757 769 A (BOIRON) 3 July 1998 (1998-07-03) claims 1,5 ----	1,6,9, 10,12
A	EP 0 286 033 A (SOCOP NAHRUNGSMITTEL) 12 October 1988 (1988-10-12) page 5, line 55 -page 6, line 8 ----	1,7-10
A	US 6 270 811 B1 (FREGONESE ALEXANDRA) 7 August 2001 (2001-08-07) claims 1-8 ----	1,6,9,10
A	EP 0 904 784 A (NUTRICIA NV) 31 March 1999 (1999-03-31) claims -----	1-3,5

INTERNATIONAL SEARCH REPORT

International application No.
EP 03/01687

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17, 18
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 17 and 18 are directed to a method of treatment of the animal body, the search has been carried out and based on the alleged effects of the composition.

Continuation of Box I.1

Claims Nos.: 17,18

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP/01687

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5968569	A	19-10-1999	AT 206873 T AU 740761 B2 AU 5040598 A BR 9800271 A CA 2222758 A1 CN 1192330 A , B DE 69707413 D1 DE 69707413 T2 DK 862863 T3 EP 0862863 A2 ES 2164299 T3 JP 10191916 A NZ 329464 A PT 862863 T ZA 9800142 A	15-11-2001 15-11-2001 16-07-1998 29-06-1999 09-07-1998 09-09-1998 22-11-2001 16-05-2002 04-02-2002 09-09-1998 16-02-2002 28-07-1998 28-01-2000 29-04-2002 08-07-1999
RU 2178975	C	10-02-2002	RU 2178975 C1	10-02-2002
DE 3536342	A	08-10-1987	DE 3536342 A1	08-10-1987
US 2002039606	A1	04-04-2002	JP 2002058434 A AU 6186101 A CA 2355527 A1 DK 200101241 A	26-02-2002 28-02-2002 21-02-2002 22-02-2003
WO 0117365	A	15-03-2001	AU 7001600 A BR 0013780 A CA 2383714 A1 WO 0117365 A1 EP 1213970 A1	10-04-2001 14-05-2002 15-03-2001 15-03-2001 19-06-2002
US 5702719	A	30-12-1997	US 5576015 A US 5705184 A	19-11-1996 06-01-1998
FR 2757769	A	03-07-1998	FR 2757769 A1	03-07-1998
EP 0286033	A	12-10-1988	DE 3711054 A1 AU 1577188 A DD 282706 A5 WO 8807580 A2 DK 483789 A EP 0286033 A2 HU 57269 A2 JP 63251079 A PL 271547 A1 PT 87141 A , B YU 65588 A1	13-10-1988 02-11-1988 19-09-1990 06-10-1988 02-10-1989 12-10-1988 28-11-1991 18-10-1988 22-01-1990 01-04-1988 30-06-1990
US 6270811	B1	07-08-2001	FR 2756181 A1 AU 5229598 A EP 0954279 A2 WO 9823243 A2 JP 2001504510 T	29-05-1998 22-06-1998 10-11-1999 04-06-1998 03-04-2001
EP 0904784	A	31-03-1999	EP 0904784 A1	31-03-1999